Anavex Life Sciences Corp (AVXL)

[XenaLives]

Close but no cigar...

I wouldn't want anyone to be disappointed because a "genetic marker" isn't named.

This is the same Phase 2a with the same tiny group and without a placebo to compare. Possibly, the only new data will be that a genetic marker will be named, specifically rather than generally, that was associated with a better outcome. The scientists and clinicians in the audience will be scanning the slides for the placebo comparator and wondering why none was included. The analysts in the room will be checking their watch to see how much longer they need to wait for BIIB's talk.

We are looking for biomarkers not genetic markers. These terms are not synonymous.

Anavex Life Sciences Provides Clinical Programs Update and Reports ...
https://www.anavex.com/anavex-life-sciences-provides-clinical-programs-update-repo...
Feb 7, 2018 - “We believe Anavex is pioneering the inclusion of advanced genomic biomarkers into late-stage CNS precision medicine trials, including our Rett syndrome, ...
Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical ...
https://www.anavex.com/anavex-life-sciences-receives-approval-to-initiate-phase-2-cli...

Jul 9, 2018 - The Company 's trial design for the Phase 2 program in PDD includes genomic, precision medicine-based biomarkers identified from patients previously treated ...
Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial ...
https://www.anavex.com/anavex-life-sciences-reports-fiscal-second-quarter-2018-fina...

May 10, 2018 - “We are looking forward, focusing on executing clinical trials using the inclusion of advanced genomic biomarkers into late-stage CNS precision medicine trials, ...
Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 ...
https://www.anavex.com/anavex-life-sciences-receives-approval-to-initiate-phase-2b-3...

Anavex Life Sciences Provides Clinical Programs ... - GlobeNewswire
https://globenewswire.com/.../Anavex-Life-Sciences-Provides-Clinical-Programs-Upda...
Feb 7, 2018 - “We believe Anavex is pioneering the inclusion of advanced genomic biomarkers into late-stage CNS precision medicine trials, including our Rett syndrome, ...

Anavex Life Sciences Receives Approval to Initiate ... - GlobeNewswire
https://globenewswire.com/.../Anavex-Life-Sciences-Receives-Approval-to-Initiate-Ph...
Jul 9, 2018 - Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ... biomarkers identified from patients previously treated with ANAVEX®2-73...

Google the two terms - it's pretty evident.

"biomarkers anavex"

"genetic markers anavex"

Perspective on future role of biological markers in clinical therapy
trials of Alzheimer’s disease: A long-range point of view beyond 2020
Harald Hampel a,
*, Simone Lista b,
*, Stefan J. Teipel c,d
, Francesco Garaci e,f
,
Robert Nistico` g,h
, Kaj Blennow i
, Henrik Zetterberg i,j
, Lars Bertram k
, Charles Duyckaerts l
,
Hovagim Bakardjian m,n
, Alexander Drzezga o
, Olivier Colliot p,q,r,s,t
, Ste´phane Epelbaum u,v
,
Karl Broich w, Ste´phane Lehe´ ricy n,p,q,r,s
, Alexis Brice p,q,r,s,x
, Zaven S. Khachaturian y
,
Paul S. Aisen z
, Bruno Dubois u,v

http://pubman.mpdl.mpg.de/pubman/item/escidoc:1982964/component/escidoc:1989744/Hampel.pdf

A Precision Medicine Initiative for Alzheimer’s disease:
the road ahead to biomarker-guided integrative disease
modeling.
Harald Hampel, Sid O’bryant, Stanley Durrleman, Erfan Younesi, Katrine
Rojkova, Valentina Escott-Price, Jean-Christophe Corvol, Karl Broich, Bruno
Dubois, Simone Lista

https://hal.inria.fr/hal-01566281/document